'People with higher Cerebral Blood Flow have 2x better shot at a longer life,' Deepinder Goyal’s Temple startup shares key ageing biomarker

In a post that has sparked fresh debate in health tech circles, Deepinder Goyal-backed wearable startup Temple shared that Cerebral Blood Flow (CBF) is a proven biomarker for ageing in its latest social media communication.

Deepinder Goyal's Temple startup says Cerebral Blood Flow (CBF) is a proven biomarker for ageing 

“Cerebral Blood Flow (CBF), a proven biomarker for aging,” the post read.

The post, published on X by Temple, states CBF’s importance in understanding brain health and longevity, drawing the attention of readers toward scientific research that links brain circulation with longer-term health outcomes.

What is Cerebral Blood Flow and how ageing is related to it?

Cerebral Blood Flow refers to the volume of blood delivered to the brain per minute, which is a critical indicator of how effectively the brain’s metabolic and oxygen needs are being met.

Temple’s post spotlighted findings from a landmark long-term study, “Total Cerebral Blood Flow and Mortality in Old Age: A 12-Year Follow-Up Study,” which tracked older adults over nearly 12 years and found that lower total CBF was significantly associated with higher risks of all-cause, cardiovascular, and non-cardiovascular mortality.

Participants in the lowest third of cerebral blood flow had almost double the risk of death compared with those in the highest CBF group, independent of other clinical risk factors, suggesting that brain perfusion is more than just a snapshot of brain health, but a long-term predictor of survival.

Temple’s emphasis on CBF fits within a broader scientific narrative associating brain perfusion with ageing; multiple studies have shown that cerebral blood flow tends to decline with age and may correlate with cognitive changes and neurodegeneration.

What is Temple?

The wearable device developed by Temple, affixed near the temple region of the head, is designed to continuously measure blood flow to the brain in real time, offering a non-invasive window into an individual’s neurological health.

Temple is focused on wearable technology aimed at monitoring cerebral blood flow in real-time. The device, known as Temple Wearable, is designed to track brain health and is connected to Goyal's Gravity Ageing Hypothesis, which suggests that gravity may reduce blood flow to the brain, potentially speeding up ageing over time.

The startup is currently in the early stages of development, with discussions about raising $50 million in seed funding to support its research and product launch

Goyal’s team positions the tool as a research-oriented device, meant to open new frontiers in the study of aging and longevity.

However, experts caution that while CBF is scientifically recognised as a meaningful measure, the wearable itself has not yet achieved clinical validation as a medical tool.

Some clinicians have described the Temple device as an experimental gadget whose health claims remain unproven and urge the public to view current demonstrations with measured scepticism.

As interest in longevity and brain health research grows, Temple’s focus on CBF places cerebral circulation firmly in the conversation as a potential biomarker for ageing, one that may bridge the gap between emerging wearable technology and foundational neurological science.

Also read: After crossing $800B net worth, Elon Musk says, ‘Money can’t buy happiness,’ Internet reacts: ‘Send me 1 million dollars’ (startuppedia.in)